RxSight, Inc. RXST

RxSight (RXST) has upside potential if it executes salesforce expansion and utilization-growth initi

ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company’s investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin

Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight’s proprietary light-adjustable technology, which allows eye surgeons to […]

RxSight Inc (RXST) navigates a challenging quarter with a 19% product sales drop while securing a transformative $200 million Alcon collaboration and planning to double its U.S. sales team.

RxSight (RXST) delivered earnings and revenue surprises of +47.62% and +2.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook. Second Quarter 2026 Highlights Total company Q2 revenue of $33.7 million, which includes $6.5 million in revenue recognized from the RxSight Alcon strategic collaborationQ2 product sales of $27.2 million including: 24,917 Light Adjustable Lens (LAL) units;12 Light Delivery Devices (LDD) unit

ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight’s common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138 shares of RxSight’s common stock to Aziz Mottiwala, RxSight’s new President and Chief Executive Officer in connection with his commencement of employment with RxSight. The inducement stock options

RxSight’s latest valuation work has taken the modelled fair value from US$9.93 to US$8.43, which points to a refreshed view of what the stock may be worth under updated assumptions. Analysts are linking this reset to softer recent Q2 trends, revised guidance, and the timing of potential contributions from the new Alcon collaboration. As you read on, you will see how these moving parts are shaping the evolving RxSight story and what to watch next in the analyst narrative. Stay updated as the...

ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer. Mr. Mottiwala brings extensive commercial leadership experience across eye care, with a proven track record of building and scaling high-performing commercial organizations. He most recently se

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Alcon Inc. (NYSE:ALC) is one of the best healthcare stocks on our list. TheFly reported on July 2 that Argus lowered its price target on ALC to $85 from $90 while maintaining a Buy rating on the shares. The firm noted […]